Special Issue

Current Concept and Management of Pediatric ATRTs

Message from the Guest Editors

Atypical teratoid rhabdoid tumors (ATRTs) are one of the CNS tumors that affect primarily infants and young children. They are fast-growing, invasive tumors with a high propensity of CSF disseminations. ATRTs present with a high case mortality following current treatment moderlities. Based on genetic and DNA methylation status and transcriptome profiles. ATRTs are further divided into three distinct molecular subgroups: ATRT-SHH, ATRT-TYR, and ATRT-MYC, This Special Issue will highlight recent advances in the biological understanding and clinical management of ATRT. deriving from preclinical, translational and/or clinical investigations. The results of innovative diagnostic modalities (molecular and imaging) will be included. The descriptions of results of case series or multi-center group studies are encouraged for a better understanding of the clinical behavior of these tumors. Reports of advanced surgical techniques for resection and also adjuvant therapy including novel moleculartargeted therapy and/or immunotherapy are welcome.

Guest Editors

Prof. Dr. Tadanori Tomita

Division of Pediatric Neurosurgery, Ann and Robert H. Lurie Children's Hospital, Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

Dr. Alicia C. Lenzen

Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA

Deadline for manuscript submissions

closed (31 July 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/186459

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

